IOP measurements appear unaffected by sponsorship of drug trials

August 2009
Ocular Surgery News;8/10/2009, Vol. 27 Issue 15, p18
Academic Journal
The article deals with a study by Yvonne M. Buys and colleagues which examined intraocular pressure (IOP) measurements in trials investigating prostaglandin analogues. According to the study, 14 trials were sponsored by the drug's parent company, five by a rival company and 15 by non-industry sources. The study also found that the mean baseline IOP between the three study groups was not significantly different.


Related Articles

  • AN IOP-SENSITIVE NEUROPATHY. Lichter, Paul R. // Ophthalmology Times;5/1/2006 Supplement, Vol. 31, p2 

    The article discusses the studies made regarding the effects of intraocular pressure (IOP) on glaucoma. Several clinical trials sponsored by the National Eye Institute, including the Early Manifest Glaucoma Trial, the Collaborative Normal Tension Glaucoma Study, the Advanced Glaucoma...

  • a global view on FIXED-COMBINATION THERAPY for glaucoma.  // Ophthalmology Times;Mar2007 Supplement, Vol. 32, p3 

    The article highlights a roundtable discussion on global perspectives regarding fixed-combination therapy for glaucoma. Since increased intraocular pressure (IOP) is the main risk factor in the progression of glaucoma, lowering IOP is the only proven target for treating glaucoma. This can be...

  • Adjuncts to prostaglandins offer expanded glaucoma treatment options. Whitson, Jess T. // Ocular Surgery News;1/25/2008, Vol. 26 Issue 2, p31 

    The article reports that prostaglandin analogues provide intraocular pressure (IOP) reduction in patients. It is mentioned that the prostaglandin analogues are utilized as first-line therapy in treating open-angle glaucoma with once-daily dosing. Agents like latanoprost (Xalatan, Pfizer)...

  • Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Sakata, R; Shirato, S; Miyata, K; Aihara, M // Eye;Dec2014, Vol. 28 Issue 12, p1446 

    PurposeAmong some local side effects of prostaglandin-associated periorbitopathy (PAP), deepening of the upper eyelid sulcus (DUES) is the most prominent clinical feature, and is one of the most significant adverse cosmetic events. Here, we prospectively investigated the incidence of DUES in...

  • Brimonidine-timolol gets good results, study shows. Guttman, Cheryl // Optometry Times;Jan2010, Vol. 2 Issue 1, p24 

    The article discusses the results of two randomized clinical trials which found that fixed combination of 0.2% brimonidine-0.5% timolol produced greater intraocular pressure (IOP) reduction compared with the fixed combination of 0.2% dorzolamide-0.5% timolol, according to optometrist Donald R....

  • Selective laser trabeculoplasly versus argon laser trabeculoplasly: results from a 1-year randomised clinical trial. Damji, K. F.; Bovell, A. M.; Hodge, W. G.; Rock, W.; Shah, K.; Buhrmann, R.; Pan, Y. I. // British Journal of Ophthalmology;Dec2006, Vol. 90 Issue 12, p1490 

    Aims: To compare selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), in terms of intraocular pressure (IOP) lowering, in patients with open-angle glaucoma. Methods: 176 eyes of 152 patients were enrolled in this study, 89 in the SLT and 87 in the ALT groups. Patients...

  • Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting β-Adrenergic Receptor 2, for Lowering Intraocular Pressure. Moreno-Montañés, Javier; Sádaba, Belén; Ruz, Verónica; Gómez-Guiu, Almudena; Zarranz, Javier; González, María Victoria; Pañeda, Covadonga; Jimenez, Ana Isabel // Molecular Therapy;Jan2014, Vol. 22 Issue 1, p226 

    The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers. The study was an open-label, controlled, single-center study comprised of two intervals that...

  • A New Era for Glaucoma Neuroprotection? Tsai, James C. // Review of Ophthalmology;Oct2004, Vol. 11 Issue 10, p105 

    The article presents information on some recent developments in glaucoma neuroprotection. Clinical studies, such as the "Ocular HypertensionTreatment Study," have focused the glaucoma community's interest intently on the benefits of intraocular pressure (IOP) reduction. These clinical studies...

  • hypertonicity.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1127 

    A definition of the term "hypertonicity," which refers to an excess of muscular or arterial tone or intraocular pressure, is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics